Trustees' Report and
Audited Financial Statements for the
Year Ended 31 March 2026 for
CHILDHOOD EYE CANCER TRUST (A COMPANY LIMITED BY GUARANTEE)
Contents of the Financial Statements for the Year Ended 31 March 2026
CHILDHOOD EYE CANCER TRUST Reference and Administrative Details for the Year Ended 31 March 2026 TRUSTEES lan Ellington - Chairman Gemma Boggs- Treasurer (resigned 22nd November 2025} Sarah VVa150n - Treasurer lappoinled 22nd November 20251 Elizabeth Coleman Alexandra Brebbia Andrea Bonzano Iresigned 23rd September 20251 Matthew Holt Rob Downes Alexis Michelle Boothroyd Ainee Ward Patrick Tonks COMPANY SECRETARY Rose-marie Sexton REGISTERED OFFICE The Royal London Hospital, Vvhilechapel Road, London, E1 1BB REGISTERED COMPANY NUMBER 02143917 (England and Wales) REGISTERED CHARITY NUMBER 327493 INDEPENDENT AUDITORS Knox Cropper LLP, Chartered Accountants and Statutory Auditors, 65 Leadenhall Street, London, EC3A2AD
CHILDHOOD EYE CANCER TRUST Report of the Trustees For the year ended 31 March 2026 The trustees who are also directors ol the charity for the purposes of the Companies Act 2006 present their report with the financial statements of the charity for the year ended 31 March 2026. The trustees have adopted the provisions of Accounting and Reporting by Charities.. Statement of Recommended Practice applicable lo charities preparing their accoun15 In a¢cordan¢e wlh the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 leffective 1 January 20191. OBJECTIVES AND ACTIVITIES Objects of thè Charity The Objects of the Charity are to promote the relief of children with retinoblastoma and to provide ongoing support for those affected. This means the Childhood Eye Cancer Trust Is dedicated to helping anyone affected by relinoblasloma (Rbl, a type Df eye cancer that affects babies and young children, mainly under the age of six. We have been supporting families since 1987. Around one child a week is diagnosed with Rb in the UK or 50 a year. It a¢¢ounls for 3% of childhood cancers in the UK and 10°A of cancers in babies under one. Around 45 % of cases are heritable and this carries wf(h it an increased risk of developing lumours in other parts of the body in later life. The Charity was originally founded to provide support and information to those affected by Rb. In 1994 we merged wth another charity that was funding research projects specifically related to Rb, and in 2004 we changed our name lo the Childhood Eye Cancer Tru51. As we grew, so did our aims and objectives and we began lo run campaigns aimed al raising awareness among health professionals and the public in order to achieve the earliest possible diagnosis for children affected. Our aims are to.. Provide support and information to families and individuals affected by Rb. Raise funds to Support research into issues Concerned diredy with Rb. Raise awareness of Rb among health professionals and others. Influence policy lo improve service delivery for those affected by Rb. Objectives. Strategies for Achievement and Public Benefit During the period of this report, we have continued lo deliver against our three core goals of support, research. and awareness. The Trustees annLJally reviewthe core goals and have reaffirmed that these remain the charitable focus. The Trustees are aware of the public benefit guidance published by the Charity Commission. We have considered the objectives of the Charity and have given regard lo how these objectives and the asso¢ialed a¢tivilies meet the public benefit criteria of advancing health, saving lives and the relief of those in need because of ill heatth. We are the only UK-wide charity providing support to people affected by Rb and we believe that they benefit from our services in the followng ways..
CHILDHOOD EYE CANCER TRUST Main Objectives Support.. To ensure that everyone affected by Rb in the UK has access to support and information according lo their need. Our Head of Support Services and Support Workers offer support to all families and individuals affected by Rb. Support is provided on the wards and in clinics at the specialist centres for Rb in the UK.. Bimiingham Women's and Children's Hospital and The Royal London Hospital. On non-clinic days, support is provided via telephone, video call, email, and social media. Support is also provided through the delivery of a programme of regular face-to-face or virtual meetings for families, teens and young adults, and adults. Our team provides signposting lo organisations for financial grants. benefits advice, therapeutic and psychological support, visual impairment support, holidays, travel expenses, white goods, and other items. Our support workers also assist rith applications for Blue Badges, Disability Living Allowance and Carer's Allowance, and housing applications. The support team collaborates wi(h the wider CHECT team with stories from members for CHECT publications, infomiation leaflets and social media. Awareness - healthcare professionals.. To save lives and minimis& the impact of visual impairment by ensuring heah¢are professionals are aware and know about Rb and its symptoms, listen lo concemed parents and make urgent referrals where necessary. Targeted activities lo healthcare professionals associated with children aged six and under. Distribution of resources that help early diagnosis and referral. Media campaigns and articles for specialist healthcare professional journals and magazines. Awar&n8ss public: To increase awareness of Rb and its signs and symptoms amongst parents, guardians and carers to promote the seeking of medical advice as soon as possible. Ensuring information for parents about the symptoms of Rb 1$ available in all relevant NHS publications and on all NHS information websites. Media activity regarding the condition including the signs and symptoms and how I where to seek help. Developing relationships with organisations able to reach large sections of the public wvch a view to raising awareness. Regular and sustsined social media aclivty wlh information and advice accessible on the Charity's website. Promoting knowledge of the possible longer-lerm impact of having had Rb as a child wlh regard lo genetics and other cancers. Information campaigns targeted towards people affected by Rb as a child.
CHILDHOOD EYE CANCER TRUST Research: Proactively engaging in the advancement of knowledge of Rb, its treatment and its impact through the awarding of grants lo groups or individuals who wsh to pursue research projects or audits lo advance knowledge of Rb and related Issues. Supporting and funding clinical, psychosocial, and scientific research relating to Rb. Vvorking through the ScientificAdvisory Committee ISACI lo identify and support suitable projects from a wide range of sources. Encouraging applications from the international research community. Supporting mulli-cenlre and international collaboration including the sharing of experience, knovAed9e, and data. The SAC is made up of experts from research and Rb-related fields. We also have three lay members representing families and the adult Rb community, and a CHECT Trustee and staff in attendance. The committee evaluates the validity and appropriateness of the proposals using an agreed scoring matrix, seeking expert review for large projects, before making recommendations to the Board for funding. Grant recipients are required lo provide six-monthly progress reports and present a final report lo the SAC and Board on the con¢lusion of the project before disseminating the findings and learning throLJgh presentations and publications. Influencing- Working with other organi5abons lo bring about improvements in the way in which services are funded and delivered in the UK. Vvorking with the treatment centres in the UK, the NHS National Commissioning Group, National Artificial Eye Service, and other umbrella bodies who provide services lo people affected by Rb. Proactively seeking partnerships rith other charities and organisalions. Volunteers 40 volunteers linduding Trustees and SAC membersl generously gave their time to support us in 2025126. Whether itwas one off or ongoing support, wewould like to thank each and every one fortheir invaluable contribution to our work. ACHIEVEMENT AND PERFORMANCE Charitablg activitiès Support Vvhilst one of our core priorities is the delivery of support to the parents and carers of children affected by Rb, we have extended this to encompass anyone affected, including teenagers whose unique needs are very different to those of a young child or baby, and adults, many of whom are living wrth the late effects of the treatment they re¢eived for Rb as a child. Membership of CHECT is open lo anyone affected by retinoblastoma las well as their friends and family). supporters of CHECT and health professionals. We do not charge a membership fee. In 2025126. 1000A of families were offered SLJPPOrt followng a diagnosis of Rb in the UK. As well as face to face, email, and telephone, we continue to use virtual platforms to support our members. There has been an increase in the number of fa¢e-lo-face sessions delivered wlh over 1,480 sessions deliVed across both treatment hospitals at inpatient and outpatient clinics.
CHILDHOOD EYE CANCER TRUST We record and monitor support interactions so that we ensure the service is meeting the needs of those affected by Rb a5 best il can. Face-to-face and remote su ort The main areas that people sought support from CHECT included". Practical and emotional support. Direct financial support and assistance with welfare applications. Detailed information about Rb including genetics, screening, fertility, and late effects of Rb. Signposting to other specialist organisalions. Vvork and employment support. Housing support. We continue lo receive a small number of enquiries from non-members. These mainly consist of international patients requesting advice and financial help as well as UK-based parents, guardians or carers who have symptom concems in their child. Social media su ort Social media is a vital source of support resources and information, with both members and non- members contacting us. We also raise awareness utilising all social media channels, including Facebook, Instagram, X, Linkedln, and TikTok. As well as our main public-facing Facebook page, we have two closed groups for members which are for parents of Childn with Rb and adults who have had Rb, both of which have seen increases in membership in the period. Financial Su ort In 2025126 we delivered 69 support grants to families and individuals to help with the costs associated th an Rb diagnosis and ongoing treatment - for example travel to and from hospital as well as occasionally helping lo buy some specialist equipment for Ih05e wlh a visual impairment. The demand for our grants continues to increase and the team continues to work in partnership with organisations to offer as much financial support as possible, especially as a number of other charitsble organisations have duced or slopped their own finan¢ial support programmes. Su ort Events In 2025126. we organised three face-to-face Family Days in Reading, Manchester and London. These included the presentation of our CHECT Champions awards to some incredibly brave and deserving children. We also ran a meet-up for adults who had had Rb where we enjoyed a boat trip down the Thames followed by lunch, and in December our annual online Christmas Quiz for teenagers and young adults was well-attended. These events provided opportunities for peer-to-peer support. Vve also worked joinuy with the oncology consultant at Birmingham Women's & Children's Hospital to host an online session for adults on Late Effects and Second Cancers. Thank you so much to Dr. Helen Jenkinson for being the lead speaker al this event.
CHILDHOOD EYE CANCER TRUST the Pen uin Pip lour enuclealion support loyl Continues lo be very popular with 27 more this year given to children who have lost an eye as part of their treatment. This tool is Ljsed by families and clinicians to normalise and explain the enucleation process. Teena e and Youn Adult TYA ort TYAS who had Rb as children can face specific challenges around self-esleem. We provide specialist support lo meet needs and facililale invaluable peer support. We have a specific website and Instagram channel for TYAS, where they can contribute stories, videos, and information appropriate to their audience. We also have a moderated closed VVhatsApp group where they keep in touch with ea¢h other. Adults Be ond Rb For some people, the effects of Rb are lifelong. We continue lo respond to the needs of adults who were affected by Rb as children. We have a Specific Beyond Rb group, the membership ofwhich has grown via a closed Facebook grtsup and a dedicated IM)alsApp Group. We also provide information on the specffjic issues faced by adults who had retinoblastoma in childhood. Partnershi Collaboration and partnership development are vital activities in the enhancement of our support provision. Our support wort(ers work very closely with the Eye Clinic Liaison Officers IECLOS) based in each specialist centre and who offer advice, infomiation and resources for children living with visual impairment. In Birmingham Women's & Children's Hospital this service is provided by the RNIB, and in the Royal London Hospital this service is provided by Guide Dogs. Ongoing partnerships continue wlh immense gratitude via organisations such as Basket Brigade UK, Box4Kids, Children In Need Emergency Fund, Chris Aked Foundation, Cyclist5 Fighting Cancer, Ellen McArthur Cancer Trust. Emily Ash Trust, Family Fund, Feed Lc>ndon. Finley's Tc>u¢h, Free Ki¢ks Foundation, Gavin Glynn Foundation, Hallie's Hideaway, The Joshua Tree, LATCH Welsh Children's Cancer Charity, Lennox Children's Cancer Fund, Miracles the Charity, Molly Ollys Wishes, Owen Mcveigh Foundation, Pajama Fairies, The Rob George Foundation and Young Lives vs Cancer. Feedback From Those Su orted 'The CHECT team is amazingly supportive and helpful. The situation families go IhroLJgh is painful enoLJgh. butthe help they give makes everything less hard for us. I don't think they realise how important they are, so BIG THANK YOU for always being there, it really makes the difference." 'IOur support workerl is amazing. She helped us with so many things. I cannot thank her enough for everything she does to help us.. °IOur support workerl has aayS been an amazing support to us. We are so grateful lo have her in our lives and on this journey with u$.
CHILDHOOD EYE CANCER TRUST °IOur support Wotkerl has been a huge emotional support for us during the hardèst year of our lives. °IOur support workerl has been a lovely person lo deal with, regularfy checks in on us when we visit, that unfortunately has been on a regular basis throughout the year. AayS available for a chal and advice. Can t thank her enough for her help wth a tough situation for the family with advice and small access to financial help. Makes our visit more pleasurable in a hospital treatment I checks every time. Awargngss Rb is a rare disease, which means that most people are not aware of it. Sadly, this can lead to a delay in a diagnosis bèing made and, because Rb is a fast-growing Cancer, quick access to treatment can be vf(al to save a child's eyes, sight and life. Raising awareness of Rb among both healthcare professionals and the public is therefore important in helping lo drive early diagnosis and as such remains a key part of our work. Pathwa stoDia nosis In 2012, as part of its aim lo reduce the delays in diagnosis of retinoblastoma experienced by some families in the UK, CHECT began to collect information from parents called 'Pathways to Diagnosis,. This information is gathered by support workers during their conversations with families and focusing on whether the families had any prior awareness of relinoblasloma.. the signs they noticed in their child's eyes that prompted them to seek help,. and the actions taken by the healthcare professionals they consulted. It is apparent that the range of experience is huge.. from families who were referred to one of the two specialist Rb cenlres in the UK within days of noticing their child's symptoms., to families who spent over six months and numerou5 visits lo various healthcare professionals before anyone recognised the significance of what they were reporting or carried out the appropriate lesls and made appropriate referrals. Recording these experiences in a quanlilative way allowed CHECT lo refine messages and information lo address those areas where it was most needed". not only to alert parents of yOLJng children. bLJt also GPS, health visitors and opticians to the main signs and symptoms of Rb, and the need for urgent examination and onward referral. In 2025, the total number of pathways collected was 39, and we reviewed the results against the ten- year average of reported figures. A while glow in the eye remains the most Common symptom overall. This year more than the 10-year average noticed a white glow in the child's eye, and slighdy fewer noticed it in a photograph. This is significant because the glow is likely to be noticeable earfier in a photo than with the naked eye. A new squint Is still the 5econd-m051 important symptom, bul 51ighlly fewerfamilies reported this as a symptom in 2024 than in other years. As usual, GPS were the first port of call for concerned families162°/ol, followed by oplicians118°kl. Other healthcare professionals ctsnsulled in the first instance were health visilors15%1, 111150hl, A&E13¢hl.
CHILDHOOD EYE CANCER TRUST Disappoints'ngly, rates of urgent referrals were down amongst GPS who examined a child with relinoblastoma134°k vs 10-year average of 47°hl, whilst opticians exceeded the 10-year average181° Vs 670kl. We saw the drop in appropriate GP referrals reflected in the tota1 rates of referrals. 47°A Df children were referred to their local ophthalmology department wlhin the recommended two weeks of seeing a healthcare professional compared lo the ten-year average of 540/0. Overall, the figures for this year were of concern. However, we are talking about a very small sample group where a few variances can impact the overall picture. Nonetheless, we will be looking carefully lo see what happens in future years, and whether thi$ is the start of a worrying decrease in rapid referrals for children with retinoblastoma from primary to secondary (local ophthalmology department) and tertiary heaf(hcare (specialist Rb cenlrel. Although Pathways to Diagnosis is designed to be a snapshot. or an indicator of trends in diagnosis in the UK, it is a key part of the resources we use to help CHECT achieve its aim of raising awareness of Rb lo aid earlier diagnosis. Public awareness.. Relinoblasloma is most often first spotted by parents or carers whether through a while glow in a family photo, a squint, or another sympltsm. Raising public awareness is therefore a vital part of our work, helping to ensure children receive a swift diagnosis. We use both traditional and digital media to reach parents and the wder public with infomialion about the signs of Rb. Media.. Previous research carried out by, or on behalf of, CHECT has shown that many people first hear about retinoblastoma through media coverage. Throughout the year we issued press releases lied to key awareness moments- including Rare Disease Day, World Retinoblastoma Awareness Week, Childhood Cancer Awareness Month and Christmas - while our felance regional journalist worked across the UK to share the stories of our CHECT Champions in local and national media. During the reporting period we received over 80 mentions in the media, giving al least 272 million people the opportunity to see or hear cc>ntent across all media outlets. Coverage included the BBC and ITV TV, radio, and digital, various national newspapers across the UK as well as coverage around the worfd. In 2025, we were also featured on BBC'S Weathemian Walking for Children in Need. We took part in the Daily Express, campaign to help change policy so that everyone who is diagnosed ¥Mth cancer is Offered mental health support- and the change in policy was successful. The campaign included sharing bmo member surveys and signing a leller to Wes Streeting. We continue lo develop and Improve the CHECT website, ensuring il is easy lo navigate and contsins relevant. useful information. Our most visited pages remain thc>se covering the white eye sign, signs & symptoms, and the causes of retinoblastoma- reflecting the public's desire to understand the condition. Despite the growing use of Al search tools, which can reduce direct website traffic, our site reached over 90,000 visitors during the year.
CHILDHOOD EYE CANCER TRUST Social Media.. Social media Is a key tool lo raise awareness of Rb. In this period, our Inslagram followers increased by 120/0 and our Facebook followers by 3%. We reached nearly 2 million people on Facebook and Instagram alone. Our TikTok channel has 350+ followers, our X channel has 2,800+ our Instagram channel for CHECT TYA has 300+ followers, and a Linkedln channel has 700+ On oin communication.. Vve di51ribule monthly newsletters and emails covering sUPPOrt, awareness, research, fundraising, storie$ and events. In 2025126 our average open rale reached 46.4% - the highest on record. We publish editions of our magazine, InFocus, each year, distributed both in print and digitally. We offset the carbon footprint of all printed Copies. We also maintain an active blog featuring news, events, real-life stories, research updates, and support article5. We are committed lo making our communication5 as inclusive and accessible as possible. We add image descriptions lo our social media posts lo ensure Content is accessible lo those who are unable to view images, and we regularly review our website to maintain accessibility stsndards. The case studies and stories we share reflect a range of relinoblasloma experiences - including those living wf(h blindness, those who have lost one or both eyes to Rb, and those who have had retinoblastoma without requiring eye removal. Research CHECT continues to fund research as a core pillar of activity with four ongoing projects.. Laborato l Basic science Professor Yellapantula.. PrognostK stratificat and eahy deleGtn of lapSed relinoblasloma using aqueous humor based cfDNA screening Cancers shed DNAfragments, called cell-free DNA IcfDNAI, into bodily fluids which facilitates detection of genomic alterations driving lumor growth. Using aqueous humor (AHI, a watery fluid that fills the eye, collected during treatment. w& will evaluate. 11 If serial monitoring of cfDNA can inform intraocular relapse of retinoblastoma earlier than clinical findings-based screening methods currently used. 21 If cfDNA prevalence at the end of treatment can inform prognosis of retinoblastoma. 31 The genomic and Clinical features that differentiate low and high risk of relapse. Professor see1.. A retinal organoKI platfonn for retinoblastoma dwg d8velopment. One challenge in developing new treatments for retinoblastoma is to preserve vision by ensuring that Rb tumour cells are killed without damaging surrounding nomial retina. For this project, we have a new approach for lesling promising retinoblastoma drugs. We Can coax adult human stem Cells lo represent normal retinal tissue in a plastic dish la"retina-in-a-dish'l. If we add human Rb lumour cells to this same 10
CHILDHOOD EYE CANCER TRUST dish, we can disrupt the retina, like an Rb tumour might do in the human eye. This mixture of Rb tumour cells with the relina-in-a-dish lets us use human cells lo see whether our new drug treatments will kill Rb ce115 specifically without harming nearby retinal cells. Thi5 new method will be very useful fortesting Rb treatments that we have developed with previous support from CHECT. Clinical Dr Zemn Onadim.. Eloise Patterson Pmiect.. Sludy of records held al The Royal London Hospital and Childhood CancerResearch Gmup on tinOblaSt0m8 patients Phase 11. This project was initially funded via 3 donation from the Greendale Fc>undation, inspired by a young adult who has previously had retinoblastoma, Eloise Patterson. Phase I (collection of clinical and mutation data and linking to Public Health England recordsl is now complete. This wll provide complete information on type tsf Rb, type of mutation, treatment, follow-up data on second primary lumours and causes of any deaths. We were delighted that the Greendale Foundation provided further support lo allow for an additional phase lo be delivered - Phase11 lslalislical analysis lo estimate risks, which it is hoped could potentially lead to earfier diagnosis and treatment of these second cancers in CLJrrent- and future- Rb populationsl, due to complete in 2026. The second phase of a pvioUSlY funded PhD project stsrted at the end of this year. Professor Bob Phillips.. Co-production of a novel psychoeduc81ion intewenlion for young people who hav& had Relinoblasloma The aim of this research is to develop, wth support from teenage and young adult survivors of retinoblastoma IRbl, an inleTvenlion to improve psychological and social wellbeing in young survivors of Rb. We believe that this will be helpful In Improving how young people think and feel and will help us to plan a feasibilty study la small-scale version of a full studyl to test how effective this intervention is, before implementing this into routine clinical practice. This research builds upon a portfolio of work in the form of a PhD funded by CHECT"Developing an evidence-based p5ycho-educalional intervention for teenagers and young adults who have had retinoblasloma.. In 2025126, we continued our Dbjeclive of delivering an annual research award, and made two new two awards.. Professor Annefte Moll.. Non-invasive cancer-lest development for the Rb-patient and Rb-survwor community Professorxu.. Decoding tumorseeding in retinoblastomè.. the genomic clues from aqueous humorliquid biopsy Our thanks go lo all members of our Scientific Advisory Committee, both lay and professional, who volunteer their time to make CHECT'S research programme possible, and thus support our aim of improving the lives of everyone affected by retinoblastoma in the fvture. 11
CHILDHOOD EYE CANCER TRUST Fundraising Fundraising Policy CHECT does not use fLJndraising services or extemal professional fundraisers to undertake its fundraising aclivilies. Additionally, no data is shared with or sold lo any external agency. The charty does not purchase external lists of potential individual donors or undertake direct mail appeals lo such The charity issues a biannual newsletter and a monthly e-newsletter I blog (both of which can be easily unsubscribed from) that share information about the charitable work and fundraising activities undertaken. The charity occasionally invites individuals to attend events but does not exert undue pressure to attend or lo dtsnate. 11 does not approach or pressure vulnerable people to support their work. A complaints policy is in pla¢e and is a¢¢essible on the charity's website IMMMf.¢hecl.org.ukl. The charity adheres lo the Fundraising Code of Practice issued by the Fundraising Regulator. Any fundraising events Carried OLJI on behalf of the charity that we are aware of are supported and monitored by the Fundraising Manager. Any marketing materials and approaches are checked to ensure that they comply wth the Fundraising Code of Practice, and details of income and expenditure are recorded by the Fundraising Manager. Income is aCknQedged, and grateful thank5 are sent, typically th a letter and certificate. In 202512026, thanks lo the generosity, creativity, and commitment of our supporters, we exceeded our budgeted income target, despite the many challenges fa¢ed by the wider chaiilable sector. From individual challenges and community evenl$ to Corporate partnerships, every donation has gone towards supporting those affected by retinoblastoma, raising awareness and investing in groundbreaking research. We are incredibly grateful and ovenNhelmed by the passion and dedication of our supporters who go to such lengths to raise funds for us. Community and Events Our Community & Events income was the highest ever. 39 supporters look part in a variety of challenge events Including marathons, half marathon5, treks and walks. And 60 Individuals. schools & nurseries and community groupslclubs took part in many fundraising events from coffee mornings to the sale of pick n mix doggie treats. To mark 10 years of opening Lambelh Palace's doors, members of the public were invited to purchase a ticket and join CHECT on 29th August to explore the history of the home of the Archbishops of Canterbury. A special mention goes lo our London Marathon team who broke all previous fundraising records. Scott & Olivia, who challenged themselves to a year of fundraising (May 2025-May 20261, taking part In many awareness campaigns and interviews and events Including the 2028 London Marathon, raised over £30.000 for CHECT. Nathan Young and three friends sel themselves a challenge lo beat the previous Guiness World Record of 32 hours of continuous padel play. In November 2025, they received the Guiness Wodd Record of 40 hours of continuous padel play and raised more than £34.000. 12
CHILDHOOD EYE CANCER TRUST Corporate Support Income from corporates remained strong with key partners including.. The Crane Fund for Widows and Children donated following a suc¢essful nomination from an employee at Crane BS&U who had retinoblastoma herself. Soop & Crooton, who provided CHECT with pro-bono marf(eting work focusing on Geofencing of GPS, placement ads and Search Engin& Oplimisalion lo help rais& awareness. This opportunity was again through an employee re¢ommendalion. Pentaco Construction who raised funds through their version of the Ryder Cup. Maximus Foundation who supported our work. Trusts & Foundatlons Income from charitable trusts and foundations totaled more than £250,000. We were delighted to continue our Ihree-year partnership wf(h BBC Children in Need and to once again become a beneficiary of the National Lottery Community Fund's Awards for All programme. We are enormously grateful to every one of the trusts and foundations that have so kindly and generously supported CHECT'S work over the past twelve months. These include mulliyear grants from the Barbara Vvard Children's Foundalitsn and the 29th of May 1961 Charitable Trust, and further support from the Eveson Trust, the February Foundation, the Greendale Foundation, the Joe Gilligan Trust, the Sophie Fitzpatrick Foundatlon, the Matthew22 Fund and many others. In Memoriam Trustees and staff would like to thank and offer sincere condolences to families and friends who have given in memory of a loved tsne during the year and are grateful lo those who have kindly remembered us in their wll. We were sad to share the news that CHECT member Robin Williams passed away in December 2025 aged 37. Robin played for England 106 time5, scoring 30 goals and represented G8 in the London 2012 Paralympic Games. A tribLJte was set up in his memory, raising ftjnds for CHECT. FINANCIAL REVIEW Reserves Policy CHECT maintains its reserves under tr0 categories.. lal unrestricted Igenerall reserves, which are available for general use in pursuance of the charity's objectives, and Ibl restricted reserves, which are for specifically earmarked purposes such as medical research or support to families belonging to a parti¢ular area. The unrestricted funds of the Charity as of 31 March 2026 lotaled £362,675. The Trustees have determined that the Charity should hold at least six months of tunning expenses in reserve. Thi5 figure represents the amount reqLJired to rLJn the charity for six months exclLJding winding LJP Costs and any special projects. Based on this calculation, the required value of reserves for the year 2025126 was £247,947. The reserves held as at 31 March 2026 represent 8.5 months of budgeted expenditure. This is intentlonal as levels of reserves are being built to allow for the delivery of member focused activities in 2027 which wll be our 40th anniversary. The Trustees review the Charity's reserves policy on a regular basis and no less than annually. The reserves position is reported al every board meeting. 13
CHILDHOOD EYE CANCER TRUST Investment Policy Funds surplus lo immediate requirements are lo be invested in interest bearing accounts wlhoul risk lo the capital. Such accounts are lo be those offered by in5titulions covered by the Financial Services Compensation Scheme IFSCSI. No more than the amount covered by the FSCS is to be invested in any one institution. FINANCIAL PERFORMANCE The 2025126 budget was set to breakeven following a number of years of deliberately operating at deficit utilising the levels of free reserves built up at the end of 2022123. The final income figure broke all previous records, allowing for additional in year expenditure on charitable activity. The total incoming resources of the Charity were £660.404, which was an increase of £141,036 on 2024125 lolal income of £519,370. Total resources expended during the year increased by £46,051 to £588,S3712024125. £542,586). Overall, the Charty recorded a surplus of £71,767 in 2025126 compared lo a deficit of £23,218 in 2024125. As of 31 March 2026, this has resulted in nel assets increasing lo £367,315, against the preceding year end of £295,548. This is comprised of £4,640 reslricled fvnds 12025126.. £6,800) and £362,675 of unreslricled funds 12025126 £288,7481. FUTURE PLANS Our vision continues lo be the primary charity in the United Kingdom dedicated lo helping families and Individuals affected by Rb. Our rnission is to lessen the impact of retinoblastoma by driving earfy diagnosis, funding research into prevention and treatment, and offering lrfelong support now and for fvlure generations. Our focus over the coming period is to.. Use the 40th anniversary In 2027 as a platform lo launch additional services. Place those that we support al the centre of everything that we do. Increase our impact by delivering improvements in the delivery of our Support, Research, Awareness, and Influence activity. Increase the levels of funds raised in an ethical and sustainable manner. Proactively seek alliances and partnerships to allow us to wden our reach, outputs, and impact. Be a caring and inclusive employer with a happy and focused team. Support The delivery of lifelong levels of support is the key focus of the charity using a support pathway that follows the key stages of the Rbjoumey- research, pre-diagnosis, diagnosls, Irealmenl, follow up, end of life. We will provide our infomiation, practical, social, financial, and emotional support at each of the above stages and Ctsnlinue the offer tsf both the direct and indirect Ipartnershipi delivered services. 14
CHILDHOOD EYE CANCER TRUST We will run events for the three main groups of members.. families., teens and young adults., and older adults (Beyond Rbl, across different regions of the UK. We will work closely ¥Mth partner organisations allowing more children and young people to experien events that can increase confidence and resilience. We will Continue to offer members memorable experiences through our special relationships wi(h organisats'ons such as the Free Kicks Foundation and Box4Kids. Research Re$ear¢h will ¢ontinue to be a vitsl focus for us and our members. We will continue lo manage and support the existing projects referenced earlier and continue our commitment tts research via another ¢all for projects and a further investment during 2026127 and beyond. Awareness The raising of awareness around the signs and symptoms of Rb with both the public and the medical profession remains a vital function. Using the "Pathway5 to Diagnosis, as the guide we will be focusing on key areas and moments in the diagnostic pathway lo ensure that the right people have the right knowledge and information al the right time. We are investing in our digital presence, creating engaging content designed to reach wider audiences and raise awareness of retinoblastoma. Influence Vve wll continue lo liaise with the different organisalions involved In a child and family's journey lo make sure the voice of our membership is heard and helps inflLJence all, to deliver the best and most effective experience to all families. Through partnership and alliance working. we wi11 look to use our position lo positively influence policy to improve the pathways and associated levels of support for all those affected by Rb. STRUCTURE. GOVERNANCEAND MANAGEMENT Govèrning documént The Childhood Eye Cancer Trust ICHECTI I'the Charity'l is a charitable company limited by guarantee Ilhe Company'l, incorporated on 1 July 1987 and a registered charity. The Company was established under a Memtrrandum ofAssociation, which estsblished the objects and powers tsf the Company and is govemed under its Articles of Association. The directors of the Company are also charity trustees for the purposes ofcharity law and are known as the board oftrustees I'the Board'l. The maximum number of Iruslees is 15. The Company's Articles were amended in 2008 to change the charity's objects and article 45 which focused on the terms of the directors. In 2009 an amendment was made to include a new article, article 60 on aulhorizing director conflicts of interest, and in 2017 the articles as a whole were replaced. In October 2022, the Articles were further amended to remove article 47 which concemed a directovs temi and abilty to apply for reflection, and to allow Society, General and Board of Trustee meetings to be held remotely. On the 23rd November 2024 the articles were revised via a special resolution al Meeting of Society Members in substitution for and lo the exclusion of all existing Arbcles of the 15
CHILDHOOD EYE CANCER TRUST Company. The revised articles ensure they are appropriate and fit for purpose, including the reduction of unnecessary administrative burdens. Oryanisational structura The Board meets a minimum of 4 times a year and at the beginning of each meeting, the trustees are requested to declare any conflicts of interest. No conflicts of interest were declared during this financial year. The Board's performance and trustees. skills are reviewed periodically and where possible new trustees are recruited to meet any needs or gaps identified. The Charity is a signatory to the NCVO'S Good Governance Code for the voluntary and community sector. To assist in the effectiveness and smooth running of the Charity, the Board continues to resoLJrce two SucoMmIttee$ to help oversee certain aspects of the Charity's work. Sub-committees are currently sel up for.. Finance, Risk and Safeguarding and for Research (Scientific Advisory Committeel. The day-to-day management of the Charity is delegated lo the CEO, supported by the staff team. At the close of the year, staffing consisted of ten staff.. a chief executive (four days per weekl., a finance manager Itwo days per weekl,. an operations & creative manager (full limel,. two fundraising managers (both full timel and one adminislralive assistsnl (two days per weekl., a head of support services (four days per weekl and two support workers- one in London IfoLJr days per weekl and one in Birmingham (four days per weekl., and a communications manager (three days per week). The Childhood Eye Cancer Trust is not affiliated with any other charitable organisation and has no related parties except as shown in the notes to the accounts. The Charity is a member Df the Association of Medical Research Charities, the National Institute of Health Research, and Cancer 52. Inductlon and tralnlng of new tru$tsos New trustees are provided with information about their role and responsibilities as recommended by the Charity Commission and the National Council for Voluntsry Organisalions INCVOI. This includes.. the Iruslee role description and person specification relevant lo the role, the Charity's confidentiality policy, and the eligibility requirements for becoming a trustee. They are also supplied with a copy of the Memorandum and Articles of Association, the annual plan and budget, all policies and procedures, financial information, risk register and the chief executive's report and minutes from two previous board meetings. Trustee roles are advertised on the CHECT website and Dn occasion, using external recruitment organi5ab"ons. Enquiries are also occasionally received from members. A selection panel made up of the Chair and CEO considers the application and the SLJitability of the applicant using agreed criteria identified on the person specification and the role description. The prospective trustee is then invited to observe a board meeting priorlo appointment and standing for election, which is voted on and approved by the Board. Induction meetings covering the background to current matters take place with the CEO and key members of the staff team. Training on matters relevant to the role and responsibilities of trustees is enuraged and the Board subscribes lo literature pertinent to good govemance. All trustees are required to sign.. a code of conduct.. the conflict-of-interest policy.. and confirmation of their eligibility to serve as a director. They also undergo enhanced with barred list checks Disclosure and Barring Service IDBSI clearance. The majDrity of trustees have personal experience of retinoblastoma and its impact, but individuals with other key skills are also recruited lo the Board lo ensure an appropriate balance to meet the needs of the Charity. 16
CHILDHOOD EYE CANCER TRUST Risk management The Iruslees regularly assess the risks to the Charity and maintain a comprehensive risk register which Includes plans to miligale or manage the risks identified. The risk register is reviewed by the Finance and Risk Committee at each of their meetings and in detail ice a year. Their discussions are reported at each Board Meeting, who in tum undertake a detailed annual review. The Chief Executive reviews on a monthly basis after which any ¢on¢ems are discussed ¥Mth the Chair of the Finance, Safeguarding & Risk Committee. In addition lo the Treasurer and Finance and Risk Committee, there are nominated trustees wf(h oversight and non-exe¢utive lead for Human Resources, Policies & Pro¢edure$. Safeguarding, and Legal Matters. The trustees are satisfied that there are systems and arrangements in place to manage the risks identified as far as possible. Safeguarding As a charity we are committed to safeguarding our employees and all those who receive and give support. Safeguarding ¢hildren, young people, and adults, w((h a focus on those who a vulnerable and may be at risk is a priority fDr the Childhood Eye Cancer Trust. Our safeguarding focus helps our trustees and employees to remove, reduce and manage safeguarding risks for those we support and work wrf(h. We review our safeguarding policy on an annual basis, have a nominated Trustee lead along wrth a staff safeguarding lead with x2 deputies, have clear and documented reporting processes and follow up on any safeguarding concerns. All staff and trustees undertake biennial safeguarding training, and undergo enhanced wlh barred Iisl checks Disclosure and Batring Service IDBSI clearance every three years. The delivery of our safeguarding obligations is person-centered, and outcomes focused, ensuring we are timely and proportionate in all our actions. STATEMENT OF TRUSTEES. RESPONSIBILITIES The Iruslees (who are a150 the directors of Childhood Eye Cancer Trust for the purposes of company lawl are responsible for preparing the Trustees, Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK anLI Republi¢ of Ireland. Company law requires the trustees to prepare financial statements for each financial year. These give true and fair view of the stale of affairs of the charitable company and Of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements. the trustees are required to select suitable accounting policies and then apply them consistently., observe the methods and principles in the Charity SORP,. make judgements and eslimales that are reasonable and prudent,. and prepare the financial slalement5 on the going-concem basis unless it is inappropriate to presume that the charitable company will continue in business. 17
CHILt)HOOD EYE CANCER TRUST for keetyng FXDppr )Urng IX)rdS whth dljcfoae vthh ve8svriatA Jrw al any IOM the an1 IK$Srt ol the ch8th8ble (xinyny. orJ to enable Ihem lo ensure th81 the finèrdal stat8rrts (xvnpty Vlth the conv8n Act 2008. They ore also rèswnsibb lor 8aTegu8rdirwJ Iho Bsset8 ol Ihe eharftable c4rnny and hone4 for tskrt r88scM 8tOP8 I PTèventK)n deledth ol fra1 arwj other lrnovLgritio9. In $0 far 0$ Ihe trustees ar8 8warg." IFr0 ts no rean1 audit infoTrIn of whh the charitabfe rMr'S aud013 arn un8w8re'. and the tru8tee8 have tsken all steps that thoy ought lo have takén to make lh0rwP Te o18ny I8VanI audlt infOrm)n and ID e#labllah that the 8udrtOTS are •w8re of that inknmkn. AUDITOR8 Tho Krw)x Cvcfp8r LLP. been rtrapOn1 with 8 un8nlnx) vot8 in f8v(¥Jr ty TnJsle8s. Thr rep(¥t b6•n pr¢Fwrod in ¢0lance wlth th SFdal rrfovl8kn8 of Part 15 ol thg comni0S t 20[ relalrt Io small conp8nios. by order of th8 Board of Truslfjes on ...... . and signed on its b8haW lan El 18
CHILDHOOD EYE CANCER TRUST REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF CHILDHOOD EYE CANCER TRUST Opinion We have audited the financial statements of Childhood Eye Cancer Trust (the 'charilable company'l for the year ended 31 March 2026 which comprise the Slalemenl of Financial Activities, the Balance Sheet, the Cash Flow Ststement, and notes to the financial slatemenls, including a summary of significant accounb'ng policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accountin9 Standards (United Kingdom Generally Accepted Accounting Praclicel, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republi¢ of Ireland,. In our opinion the financial statement5'. give a true and fair view of the stsle of the charitable company's affairs as at 31 March 2026 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended., have been properly prepared in accordance wth United Kingdom Generally Accepted Accounting Pra¢tice. in¢luding Finan¢ial Reporting Stsndard 102 'The Financial Reporting Stsndard appli¢able in the UK and the Republic of Ireland,; and have been prepared in accordance with the requirements of the Companies Act 2006. Basis for Opinion We cc)nducted our audit in accordance with International Stsndards on Auditing IUKI IISAS IUKII and applicable law. Our responsibilities under those standards are fvrther described in the Auditors responsibilities for the audf( of the financial slalemenls section of our report. We ale independent of the charitable ¢ompany in a¢¢ordan¢e with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC'S Ethical Standard, and we have fvlfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our tspinion. Conclusions Ralating to Going Concem In auditing the financial statements, we have concluded that the Iruslees, use of the going concem basis of atrUntIng in the preparation of the financial stslements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may ca51 significant doubl on the charitable company's ability lo ¢ontinue as a going ¢on¢ern for a period of al least twelve months from when the financial statements are authDrised for issue. Our resptsnsibililies and the responsibilities of the Iruslees with respect lo going concern are described in the relevant sections of this report. other Inforniation The Iruslees are responsible for the other information. The other information comprises the Infotmalion included in the annual report. other than the financial statements and our Report of the Independent Auditors thereon. Our opinion on the financial slalemenls does not cover the other infomalion and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. 19
CHILDHOOD EYE CANCER TRUST In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent wlh the financial statements or our knowledge obtained in the audit or olherw5e appears lo be materially mi5Staled. If we identify such material inconsistencies or apparent material misstatements, we are required to detemiine whether there is a material misstatement in the financial statements or a material misslalemenl oflhe other information. If, based on the work we have performed, we conclude that there is a material misslatemenl of this other infomiation, we a required to report that fact. We have nothing to report in this regard. Opinions on Other Matters Prescribed by the companies Act 2006 In our opinion, based on the work undertaken in the course of the audit.. the information given in the Report of the Trustees, which includes the Directors, Report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is ¢tsnsistenl with the financial stslements", and the Report of the Trustees has been prepared in a¢¢ordance with applicable legal requirements. Matters on Which we are Required to Report by Exception In the light of the knowledge and understanding of the ¢haritsble company and ils environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees. Vve have nothing to report in respect of the ftsllowing matters where the Companies Act 2006 requires LJS to report to you if, in our opinion.. adequate accounting records have not been kept or retums adequate for our audit have not been received from branches not visited by us., or the financial statements are not in agreement wlh the accounting records and returns., or certain dis¢losures of trustees, remuneration specified by law are not made., or we have not received all the informatiDn and explanations we require for our audit., or the trustees were not entitled to take advantage of the small companies exemption from the requirement to prepare a Strategic Report or in preparing the Report of the Trustees. Responsibilitios of Trustaes As explained more fully in the Statement of Trustees Responsibilities, the Iruslees (who are also the directors of the Charitsble Company for the purposes of company lawl are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misslalemenl, whether due to fraud or error. In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concem, disclosing, as applicable, matters related to going concem and using the going concem basis of accounting unle55 the Iruslees either intend to liquidate the charitable company or lo cease operations, or have no realistic alternative but to do so. Auditor's Responsibilities for the Audit of the Financial Statsments Our objectives are to obtain reasonable assurance about whether the financial slalemenls as a whole are free from material misstatement, ¥fvhelher due lo fraud or error. and lo issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance but Is not a guarantee that an audrt conducted in accordance wf(h ISAS IUKI will always delecl a material misslalemenl when It exists. Misslatemenls can arise from fraud tsr error and ar& considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. 20
CHILDHOOD EYE CANCER TRUST Irregularities, including fraud, are instances of non-compliance wlh laws and regulations. We design procedure5 In line with our re5ponsibililie5, outlined above, to delect material mi5slalements in respect of irregLJlarities, inclLJding fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.. The charitable company is required to comply with both company law and charity law as applicable in England and Wales and, based on our knoedge of its aclivilies, we identified that the legal requirement to accurately account for restricted funds was of key significance. We gained an understanding of how the charitable company complied with its legal and regulatory framework, including the requirement to properly account for restricted funds, through discussions with management and a review of the docLJmented policies, procedures, and controls. The audit team, which is experienced in the audit of charities, considered the charitable company's susceptibility to material misstatement and how fraud may occur. Our considerations included the risk of management override. Our approach was lo che¢k that all reslricled income was properly identified and separately accounted for and to ensure that only valid and appropriate expenditure was charged to restricted funds. This included reviewng journal adjustments and unusual transactions. A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uklauditorsresponsibilities. This description fomis part of our Report of the Independent Auditors. Uso ofour Roport This report is made solely to the charitable company's rnembers, as a body, in accordance with Chapter 3 tsf Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might slal& to the ¢harilable company's members those matters we are quired lo slate lo them in an auditors, port and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility lo anyone other than the charf(able company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed. Richard Billinghurst FCA (Senior Statutory Auditor) for and on behalf of Knox Croppor LLP 6S Leadenhall Street London EC3A 2AD 0811012026 Data: ............................................. 21
| 2025 | |||||
|---|---|---|---|---|---|
| Unrestricted | Restricted | 2026 | Total | ||
| funds | funds | Total funds | funds | ||
| Notes | £ | £ | £ | £ | |
| INCOME AND ENDOWMENTS | |||||
| FROM: | |||||
| Donations and Legacies | 2 | 407,892 | 238,251 | 646,143 | 507,970 |
| Other Trading Activities | 3 | 1,180 | - | 1,180 | 843 |
| Investment Income | 4 | 13,081 | - | 13,081 | 10,557 |
| Total | 422,152 | 238,251 | 660,404 | 519,370 | |
| EXPENDITURE ON: | |||||
| Raising Funds | 5 | 178,146 | - | 178,146 | 154,967 |
| Charitable activities | 6 | ||||
| Medical Research and Grant | 38,829 | 42,130 | 80,959 | 102,137 | |
| Making | |||||
| Awareness Raising | 105,291 | 10,000 | 115,291 | 111,526 | |
| Family Support and Information | 287 | 188,281 | 188,569 | 154,415 | |
| Influencing | 25,671 | - | 25,671 | 19,541 | |
| Total | 348,225 | 240,411 | 588,637 | 542,586 | |
| NET INCOME/(EXPENDITURE) | 73,927 | (2,160) | 71,767 | (23,216) | |
| RECONCILATION OF FUNDS | |||||
| Total Funds Brought Forward | 288,748 | 6,800 | 295,548 | 318,764 | |
| TOTAL FUNDS CARRIED | |||||
| FORWARD | £362,675 | £4,640 | £367,315 | £295,548 |
CHILDHOOD EYE CANCER TRUST CMLI)IIOOD EYE CAIICEII TRV8T IREOISTEReD NUM8ER.' 02143•1 BALANCE SHEET AT 31 MARCH 2028 2028 2025 CURRENT ASSETS [blO15 C•sh at Bank aNI in Harnl 12 17,360 663,347 670.707 34.887 473,048 507,935 CREDITORS Amounts Falling Du6 Illthin Ono Year NET CURRENT ASSErs 13 190,892 313,815 137,75 370.178 TOTAL ASSETS LESS CURRENT LIABILITIES CREDITORS Amowts FaKlity After Mcn Than Ono Year NET ASSETS 379,815 370,178 14 12,500) £367.316 (74.830) £295,548 FUNDS UnreStn¢1 funds Restricled funts TOTAL FUNDS 16 2.676 288,748 6.800 £295,548 £367.315 finarla1 stAtements hav8 twn prgpared in a¢cx)rd8n(¥ with the pro¥is*)rva applicable to The financial stslewents apwov&J by tho Bowd of Trustges on ..... ... s•JnwJ on ils behall try.. 23
CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917) CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH 2026
| Notes | 2026 | 2025 | |
|---|---|---|---|
| £ | £ | ||
| Cash flows from operating activities: | |||
| Cash Generated from Operations | 19 | 67,215 | (16,067) |
| Finance Costs Paid | - | - | |
| Net Cash (Used in)/Provided by Operating | |||
| Activities | 67,215 | (16,067) | |
| Cash Flows from Investing Activities: | |||
| Interest Received | 13,081 | 10,557 | |
| Net Cash Provided by Investing Activities | 13,081 | 10,557 | |
| Change in Cash and Cash Equivalents in | |||
| reporting period | 80,296 | (5,510) | |
| Cash and cash equivalents at beginning of | |||
| reporting period | 473,047 | 478,558 | |
| Cash and cash equivalents at end of reporting | |||
| period | £553,347 | £473,048 |
1. Accounting Policies
Basis of preparing the financial statements
The financial statements of the Charity, which is a public benefit entity under FRS 102, have been prepared in Recommended Practice applicable to charities preparing their accounts in accordance with the Financial panies Act 2006. The financial statements have been prepared under the historical cost convention.
Going concern
cash flows for the following year are sufficient such that the Charity remains a going concern for the foreseeable future, being a period of at least 12 months from the date of approval of these financial statements. In making this judgement, the trustees and senior management team have considered future agreed funding and the anticipated impact of external factors on future funding and expenditure.
Critical accounting judgements and key sources of estimation uncertainty
The preparation of financial statements in accordance with generally accepted accounting practice requires management to make estimates and judgements that affect the reported amounts of assets and liabilities at the reporting date and the reported amounts of revenues and expenses during the reporting period. The critical judgements and estimates are reflected in these accounting policies.
Income
All incoming resources are included in the Statement of Financial Activities when the Charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income when appropriate:
-
Voluntary income is received by way of grants, donations and gifts and is included in full in the Statement of Financial Activities when receivable. Grants, where entitlement is not conditional on the delivery of a specific performance by the Charity, are recognised when the Charity becomes unconditionally entitled to the grant.
-
Donated services and facilities are included at the value to the Charity only where this can be quantified. The value of services provided by volunteers has not been included in these accounts. Donated goods are measured at fair value and included within income.
-
Investment income is included when receivable.
Expenditure
Expenditure is recognised on an accrual basis as a liability is incurred. Expenditure includes any VAT that cannot be fully recovered, and is reported as part of the expenditure to which it relates:
-
Costs of generating funds comprise the costs associated with attracting voluntary income. Charitable expenditure comprises those costs incurred by the Charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.
-
Governance costs include those costs associated with meeting the constitutional and statutory requirements of the Charity and include audit fees and costs linked to the strategic management of the Charity.
-
All costs are allocated between the expenditure categories of the Statement of Financial Activities on a basis designed to reflect the use of the resource. Costs relating to a particular activity are allocated directly, others are apportioned on an appropriate basis e.g. time or estimated usage basis as set out in the notes to these accounts.
1. Accounting Policies continued
Tangible fixed assets
Tangible fixed assets are stated at cost less accumulated depreciation. The cost of minor additions or those costing below £250 are not capitalised. Depreciation is provided at rates calculated to write off the cost of each asset over its expected useful life, which in all cases is estimated at 4 years.
Cash at bank and in hand
Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.
Debtors
Trade and other debtors are recognised at the settlement amount due. Prepayments are valued at the amount prepaid net of any trade discounts due.
Creditors
Creditors are recognised at their settlement amount, after allowing for any trade discounts due.
Financial instruments
The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.
Employee benefits
Short-term benefits are recognised as an expense in the period in which the service is received. Termination benefits are accounted for on an accrual basis and in line with FRS 102. The Charity operates a defined contribution pension scheme. Contributions are charged to the Statement of Financial Activities in the period to which they relate and are allocated between activities and funds based on the use of the resource i.e. where employees spend their time.
Taxation
The Charity is exempt from corporation tax on its charitable activities.
Fund accounting
Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees. Restricted funds can only be used for particular restricted purposes within the objects of the Charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes. Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.
Hire purchase and leasing commitments
Rentals paid under operating leases are charged on a straight-line basis over the period of the lease.
2. Donations and Legacies
| Donations and Legacies | ||||
|---|---|---|---|---|
| Unrestricted | Restricted | Total | Total | |
| funds | funds | 2026 | 2025 | |
| £ | £ | £ | £ | |
| Grants | ||||
| Grants from Trusts & Foundations | 16,050 | 238,251 | 254,301 | 201,597 |
| 16,050 | 238,251 | 254,301 | 201,597 | |
| Donations: | ||||
| General Donations | 32,314 | - | 32,314 | 24,893 |
| Standing Orders | 25,885 | - | 25,885 | 29,618 |
| In Memoriam | 29,194 | - | 29,194 | 32,516 |
| GAYE | 9,292 | - | 9,292 | 2,126 |
| Collecting Tins | 671 | - | 671 | 457 |
| Other Corporate Donations | 42,728 | - | 42,728 | 20,604 |
| London Marathon | 68,116 | - | 68,116 | 45,837 |
| Great North Run | 8,338 | - | 8,338 | 21,319 |
| Other events, Sporting Activities | 175,303 | - | 175,303 | 129,003 |
| and Community Fundraisers | ||||
| 391,842 | - | 391,842 | 306,373 | |
| Legacies | - | - | - | - |
| Total Income from Donations | £407,892 | £238,251 | £646,143 | £507,970 |
| and Legacies |
The Trustees would like to thank all the members and supporters who have contributed their time and effort to raising money for the Trust.
3. Other Trading Activities
| 2026 | 2025 | |
|---|---|---|
| Total | Total | |
| £ | £ | |
| Christmas Cards | 453 | 465 |
| Merchandise Sales | 727 | 378 |
| £1,180 | £843 | |
| Investment Income | ||
| 2026 | 2025 | |
| Total | Total | |
| £ | £ | |
| Bank Interest | 13,081 | 10,557 |
| £13,081 | £10,557 |
4. Investment Income
5. Raising Funds
| 2026 | 2025 | |
|---|---|---|
| Total | Total | |
| £ | £ | |
| Raising Donations and Legacies | ||
| Staff Costs | 134,774 | 100,911 |
| Fundraising Costs | 23,516 | 14,259 |
| Support Costs | 19,856 | 39,797 |
| £178,146 | £154,967 |
6. Charitable Activities
| Grant | Support | Support | ||||
|---|---|---|---|---|---|---|
| Direct Costs | Funding of | Costs | (see | 2026 | 2025 | |
| Activities | note | 7) | Total | Total | ||
| £ | £ | £ | £ | |||
| Medical Research and | ||||||
| Grant Making | 54,885 | 22,704 | 3,370 | 80,959 | 102,137 | |
| Awareness Raising | 3,091 | 97,617 | 14,583 | 115,291 | 111,526 | |
| Family Support and | ||||||
| Information | 27,198 | 140,523 | 20,848 | 188,569 | 154,415 | |
| Influencing | - | 22,353 | 3,318 | 25,671 | 19,541 | |
| £85,174 | £283,197 | £42,120 | £410,490 | £387,619 |
7. Support Costs
Support costs are allocated to activities on the basis of staff time. In the current year support costs have been reanalysed for the financial statements to better reflect the figures which are provided in the management accounts. *The allocation of salary costs has been reviewed to ensure that expenditure is presented consistently with the underlying accounting records and management accounts. In a change to 2025, the current year salary costs (2026) have been allocated directly to the relevant charitable activity cost centres, rather than initially being recorded within support costs and subsequently reallocated. This change affects the presentation of costs only and has not resulted in any material change to the overall allocation of salary costs between activities compared with the prior year.
Governance costs of £8,085 are included in support costs.
| Raising | Medical | Family Support | Total Activities | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Donations and | Research and | Awareness | and Information | 2026 | Total Activities | ||||
| Legacies | Grant Making | Raising | Influencing | 2025 | |||||
| £ | £ | £ | £ | £ | £ | £ | |||
| Salaries | 3,280 | 557 | 2,409 | 3,444 | 548 | 10,238* | 109,007 | ||
| Premises Rent | 4,428 | 752 | 3,252 | 4,650 | 740 | 13,822 | 9,065 | ||
| Premises Costs | 310 | 53 | 227 | 325 | 52 | 966 | 137 | ||
| Insurance | 336 | 57 | 247 | 353 | 56 | 1,050 | 931 | ||
| Communications and Stationery | 7,351 | 1,248 | 5,399 | 7,718 | 1,228 | 22,944 | 19,915 | ||
| Meetings, Seminars and Staff Training | 397 | 67 | 292 | 417 | 66 | 1,240 | 728 | ||
| Travel and Subsistence | 300 | 51 | 220 | 315 | 50 | 937 | 503 | ||
| Recruitment | - | - | - | - | - | - | 648 | ||
| Accountancy Fees | 766 | 130 | 563 | 805 | 128 | 2,392 | 9,926 | ||
| Sundries | 381 | 67 | 288 | 412 | 66 | 1,223 | 800 | ||
| Bank Charges | 123 | 21 | 90 | 129 | 21 | 383 | 290 | ||
| 2,172 | 369 | 1,595 | 2,281 | 363 | 6,780 | 7,237 | |||
| £19,856 | £3,370 | £14,583 | £20,848 | £3,318 | £61,976 | £159,187 |
8. Net Income (Expenditure)
| 2026 | 2025 | |||
|---|---|---|---|---|
| Total | Total | |||
| £ | £ | |||
| Auditors Remuneration | 6,780 | 6,420 | ||
| Depreciation Owned Assets |
- | - | ||
| Non Audit Services | 1,200 | 1,200 |
for the year ended 31 March 2025.
Trustees Expenses
During the current year £105 of expenses were reimbursed to the Trustees (2025: £85).
10. Staff Costs
| 2026 | 2025 | |
|---|---|---|
| Total | Total | |
| £ | £ | |
| Wages and Salaries | 377,754 | 373,078 |
| Social Security Costs | 38,782 | 28,855 |
| Other Pension Costs | 11,672 | 11,141 |
| £428,208 | £413,074 |
The average monthly number of employees during the year was as follows:
| 2026 | 2025 | |
|---|---|---|
| Total | Total | |
| Average Number of Employees | 10 | 10 |
The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:
| 2026 | 2025 | ||
|---|---|---|---|
| Total | Total | ||
| £ | £ | ||
| £70,000 | - £80,000 | 1 | 1 |
CHILDHOOD EYE CANCER TRUST 11. Comparatives For the Statement of Financial Activities Unrnstrictsd Fund Restrict Funds Total Funds INCOME AND ENDOWMENTS FROM Donations and Legacies 334,637 173,333 507,970 Other Trading Activities Investment Income 843 10,557 843 10,557 Total 346,037 173,333 519,370 EXPENDITURE ON Raising Funds 154,967 154.967 Charitsble Activities Medical Research and Grant Making Awareness Raising Family Support and Information Influencing 77,537 111.526 5,682 19,541 24,600 102,137 111.526 154.415 19,541 148,733 Total 369,253 173,333 542,586 NET INCOME IIEXPENDITUREI 123,2161 123,2161 RECONCIUATION OF FUNDS Total Funds Brought Forward 311,964 6,800 318,764 TOTAL FUNDS CARRIED FORWARD £288,748 £6,800 £295,548 12. Debtors.. Amounts Falling Due Within One Year 2026 Total 2025 Total Trade Debtors Other Debtors Prepayments and Accrued Income 14,859 7,388 12,640 2.792 14.569 £17,360 £34,887 31
CHILDHOOD EYE CANCER TRUST 13. Creditors.. Amounts Falling Due Within One Year 2026 Total 2025 Total Trade Creditors Pension and PAYE Creditor Deferred Income AccrLJals 29.595 7.754 47,205 106.338 1,515 66,275 69,967 £190.892 £137,757 InclLJded within Accruals is £87,313 for resear¢h grants awarded but expe¢ted lo be drawn do¥Nn within 12 months of the year end12025.' £62,315). Deferred income relates lo donations received in respect of future events, all of which is released in the followng finan¢ial year. 14. Creditors.. Amounts Falling Due After One Year 2026 Total 2025 Total Accruals and Deferred Income £12.500 £74,630 Accruals reflect grants awarded but not expected to be drawn down until more than 12 rnonths after the current year end. 15. Leasing Agreements Minimum lease payments under non-cancellable operating leases fall due as follows 2026 Total 2025 Total Within One year The current lease expired in August 2025, with no commitment remaining. A new lease was signed in August 2025 for a two-year period wth a six-monlh notice period. 32
CHILDHOOD EYE CANCER TRUST 16. Analysis of Net Assets Between Funds Unrnstrictsd Fund R&strictad Funds 2026 Total Funds 2025 Total Funds Current Assets Current Liabilities Long Term Liabilities S66,067 1190,8921 112.5001 4.640 570,707 1190,8921 112,5001 507,934 1137,7571 174,6301 £362,675 £4,640 £367,31S £295,547 17. Movement In Funds Net Movement in Funds At 1.4.2S At 31.3.26 Unre$tri¢ted Funds General Fund 288.748 73,927 362,675 Restrictsd Funds Family Support 6,800 {2,1601 4,640 TOTAL FUNDS 295.548 71.767 367,315 Net movement in fvnds, included in the above are as follows.. Incoming Resources Rosourcas Expended Movement in Funds Unrestricted Funds General Fund 422,152 1348,22SI 73.297 Restricted Funds Awareness Raising Family Support Research 10.000 188,121 42.130 110.0001 1188,2811 142,130 12,1601 TOTAL FUNDS 238.251 240.411 71.767 33
CHILDHOOD EYE CANCER TRUST 17. Movement In Funds - continued Comparativos for Movèment in Funds Nat Movement in Funds At 1.4.24 At 31.3.25 Unrastrictsd Funds General Fund 311,964 123,2161 288,748 Restricted Funds Family Support 6,800 6,800 TOTAL FUNDS 318,764 123,2161 295,548 Comparative net movement in fvnds, included in the above are as follows.. Incoming Resources Resources Expended Movement in Funds Unrestrl¢ted Funds General Fund 346,037 1369,2531 123,2161 Rostrictsd Funds Family Support 148,733 24,600 1148.7331 124,6001 TOTAL FUNDS 519,370 1542,5861 123,2161 Purposes of Restricted Funds Medical Research Available for reSeah into various projects that promote the objects of the Charity Support To provide support and information to families and individuals affected by retinoblastoma. Kent Travel Afund lo provide eligible families living in Kent wlh one-off travel grants for financial assistance with travel to UK clinics. 18. Related Party Disclosures There were no related paty transactions for the year ended 31 March 2026. 34
CHILDHOOD EYE CANCER TRUST 19. Reconciliation of Net (Expenditure)Ilncome To Net Cash Flow From Operating Activities 2026 Total 2025 Total Net IncomellExpenditure} for the reporting period las per the Statomant of Financial Activitiès) Adjustments for: Interest Received Decreaselllncrease) in Debtors IDecreasel/lncrease in Creditors 71.767 123,2161 113,0811 17.526 18,9981 110,5571 114,1161 31,822 Net Cash provided byllused in) operations £67.215 £116,0671 20. Analysis Of Changes In Net Funds At 1.4.25 Cash Flow At 31.3.26 Net Cash Cash at Bank 473,047 67,215 553,347 Total 473,047 £67,215 £553,347 21. Capital Commitments At the year end the Board had agreed to commit to £12,500 of research expenditure for 2026- 2027. 35